IRAK1 and diffuse large B-cell lymphoma: Targeting the IRAK1/4 signaling pathway has emerged as a promising therapeutic strategy for various malignancies, including diffuse large B-cell lymphoma (DLBCL), myelodysplastic syndrome, breast cancer, head and neck cancer, and pancreatic cancer.